Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT02954081 Completed - Psoriasis Clinical Trials

APremilast After FumaRic Acid Ester Treatment

APART
Start date: January 26, 2017
Phase:
Study type: Observational

Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment

NCT ID: NCT02951533 Completed - Psoriasis Clinical Trials

A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

POLARIS
Start date: December 12, 2016
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type psoriasis who have not yet received any systemic therapy.

NCT ID: NCT02949388 Completed - Clinical trials for Chronic Stable Plaque Psoriasis

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.

NCT ID: NCT02944630 Recruiting - Psoriasis Clinical Trials

Psychotherapy for Patients With Psoriasis: Effects in Quality of Life

Start date: October 2016
Phase: N/A
Study type: Interventional

The aim of this study is to determine the benefits of individual psychotherapy on quality of life for people with psoriasis receiving medical treatment versus a control group (awaiting group) treated with medical treatment, without psychotherapy.

NCT ID: NCT02940561 Recruiting - Clinical trials for Rheumatoid Arthritis

BE Study in Patients - Methotrexate Tablets

Start date: August 2016
Phase: Phase 1
Study type: Interventional

To characterize the pharmacokinetic profile of the Test product - Methotrexate Tablets USP, 2.5 mg of Amneal Pharmaceuticals, compared to that of the corresponding Reference product - Methotrexate Tablets USP 2.5 mg manufactured for DAVA Pharmaceuticals, Inc. in patients with mild to severe psoriasis or rheumatoid arthritis, who are already on established regimens of 2.5 mg every 12 hours for three doses per week under fasting conditions, and to assess their bioequivalence.

NCT ID: NCT02940002 Completed - Psoriasis Clinical Trials

BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test

Start date: October 12, 2016
Phase: Phase 1
Study type: Interventional

To explore the efficacy and safety of four BAY1003803 formulations by means of a within subject comparison in an open Psoriasis Plaque Test

NCT ID: NCT02936492 Terminated - Psoriasis Clinical Trials

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Start date: October 24, 2016
Phase: Phase 1
Study type: Interventional

Systemic safety following single and multiple dermal administration of BAY1003803

NCT ID: NCT02935582 Completed - Psoriasis Vulgaris Clinical Trials

PSOREAL - Managing PSOriasis in the REAL World

PSOREAL
Start date: January 2017
Phase:
Study type: Observational

Multinational real-life study of current psoriasis treatment strategies, topical treatment patterns and treatment outcomes of these treatments, including the newly introduced calcipotriol/betamethasone dipropionate aerosol foam fixed combination product Enstilar® (calcipotriol/betamethasone dipropionate).

NCT ID: NCT02934412 Completed - Psoriasis Clinical Trials

A Study of SHR-1314 in Healthy Subjects

Start date: August 22, 2016
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single dose escalating, study in 5 sequential cohorts to investigate the effect of a single s.c. injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects. Each cohort will consist of 6 subjects receiving active drug and 2 subjects receiving placebo, for a total of approximately 40 subjects dosed at one study site.

NCT ID: NCT02933866 Completed - Scalp Psoriasis Clinical Trials

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

Start date: March 11, 2016
Phase: Phase 3
Study type: Interventional

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis